Anne Billings, MED, CCC-SLP | |
538 W 2nd St, La Place, LA 70068-6802 | |
(985) 652-7233 | |
(985) 652-2763 |
Full Name | Anne Billings |
---|---|
Gender | Female |
Speciality | Speech-language Pathologist |
Location | 538 W 2nd St, La Place, Louisiana |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1376629956 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
235Z00000X | Speech-language Pathologist | 2962 (Louisiana) | Primary |
Mailing Address | Practice Location Address |
---|---|
Anne Billings, MED, CCC-SLP 24 Pampas Dr, La Place, LA 70068-6407 Ph: () - | Anne Billings, MED, CCC-SLP 538 W 2nd St, La Place, LA 70068-6802 Ph: (985) 652-7233 |
News Archive
A phase III randomised controlled trial shows that intrathoracic radiotherapy after chemotherapy significantly reduces the chances of disease progression in patients with extensive-stage small-cell lung cancer.
Physical activity not only reduces the risk of stroke. Individuals who walk at least 30 minutes a day also have a lower risk of severe stroke, according to a new study in Neurology.
Curis, Inc., an oncology focused company developing novel, targeted drug candidates for the treatment of human cancers, and Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology as well as companion diagnostics, today announced presentation of data for Debio 0932 at the Annual Meeting of the American Association for Cancer Research (AACR) that demonstrated synergy between Debio 0932 and various standard of care (SOC) agents in multiple in vitro and xenograft models of non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC).
Sanofi-aventis announced today results of a head-to-head study providing further evidence on the efficacy of once-daily, 24-hour basal insulin Lantus(R) (insulin glargine (rDNA) injection) compared to twice-daily insulin detemir. The study was presented during the 45th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna.
› Verified 7 days ago
Mrs. Mary Terrell, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 513 Palm St, La Place, LA 70068 Phone: 830-370-2418 | |
Mrs. Kristen Moore Stpierre, MA CCC SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1729 E Frisco Dr, La Place, LA 70068 Phone: 985-651-9812 | |
Joanna Hastings, MS-CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 538 W 2nd St, La Place, LA 70068 Phone: 985-652-7233 Fax: 985-652-2763 | |
Leslye Mcallister-young, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 538 W 2nd St, La Place, LA 70068 Phone: 985-652-7233 | |
Mrs. Heather Abadie, M.C.D., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 538 W 2nd St, La Place, LA 70068 Phone: 985-652-7233 Fax: 985-652-2763 | |
Danielle F Folse, M.ED., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 538 W 2nd St, La Place, LA 70068 Phone: 985-652-7233 Fax: 985-652-2763 |